Securities fraud class action filed against Microvast, compounding existing solvency and operational headwinds.

What happened

A securities class action has been filed against Microvast, alleging the company misled investors about its ability to achieve targeted profit margins and complete the Huzhou expansion on schedule during the April 2025 to March 2026 period. This litigation arrives as the company navigates a severe liquidity crunch, with the May 2026 convertible loan maturity unresolved and Q1 2026 revenue collapsing 48% YoY on a 49% shipment drop. The lawsuit’s claims directly target the management optimism that accompanied the FY2025 earnings release, which preceded the auditor’s going-concern warning and the subsequent operational deterioration. While the legal outcome remains uncertain, the suit adds distraction and potential settlement costs at a time when cash preservation and execution focus are paramount. The news reinforces the existing bearish thesis that Microvast’s equity is a going-concern gamble with multiple downside triggers.

Implication

Investors must now price in potential legal liabilities and defense costs, which further strain the company’s fragile balance sheet and may push management to prioritize litigation over operational turnaround. The lawsuit could also dampen sentiment among customers and partners, slowing backlog conversion and hurting the revenue recovery thesis that underpins any bullish scenario. With the bear case already at a 35% probability and an implied value of $0.85, this development tilts the risk-reward even more unfavorably, suggesting a lower fair value. Any delay in resolving the convertible loan maturity now faces the added overhang of an active securities fraud claim, making an attractive entry even more elusive. We maintain our WAIT rating but stress that the thesis is increasingly fragile; only concrete evidence of financing resolution and shipment recovery can justify taking a position.

Thesis delta

The class action raises the probability of the bear scenario, as it adds legal expenses and reputational damage that could further impair the company’s already-strained liquidity and execution. While our WAIT rating stands, the thesis now requires an even wider margin of safety—we would lower our attractive entry to below $0.85—and the burden of proof for the bull case rises meaningfully.